Connection

David Ho to Antibodies, Viral

This is a "connection" page, showing publications David Ho has written about Antibodies, Viral.
Connection Strength

0.562
  1. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. Cell Host Microbe. 2021 05 12; 29(5):747-751.e4.
    View in: PubMed
    Score: 0.089
  2. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021 05; 593(7857):130-135.
    View in: PubMed
    Score: 0.088
  3. SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease. Emerg Microbes Infect. 2020 Dec; 9(1):2091-2093.
    View in: PubMed
    Score: 0.087
  4. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature. 2020 08; 584(7821):450-456.
    View in: PubMed
    Score: 0.085
  5. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J Virol. 2005 Mar; 79(5):2678-88.
    View in: PubMed
    Score: 0.029
  6. SARS-CoV-2 Transmission Risk Among National Basketball Association Players, Staff, and Vendors Exposed to Individuals With Positive Test Results After COVID-19 Recovery During the 2020 Regular and Postseason. JAMA Intern Med. 2021 07 01; 181(7):960-966.
    View in: PubMed
    Score: 0.023
  7. Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies. Structure. 2021 07 01; 29(7):655-663.e4.
    View in: PubMed
    Score: 0.023
  8. Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class. Cell Rep. 2021 04 06; 35(1):108950.
    View in: PubMed
    Score: 0.022
  9. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe. 2021 05 12; 29(5):819-833.e7.
    View in: PubMed
    Score: 0.022
  10. Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies. Cell Host Microbe. 2021 04 14; 29(4):551-563.e5.
    View in: PubMed
    Score: 0.022
  11. In vivo expressed biologics for infectious disease prophylaxis: rapid delivery of DNA-based antiviral antibodies. Emerg Microbes Infect. 2020 Dec; 9(1):1523-1533.
    View in: PubMed
    Score: 0.022
  12. Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. Cell Rep. 2020 10 27; 33(4):108322.
    View in: PubMed
    Score: 0.022
  13. Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus. Appl Microbiol Biotechnol. 2007 Oct; 76(5):1131-6.
    View in: PubMed
    Score: 0.009
  14. SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus. Vaccine. 2005 Oct 10; 23(42):4959-68.
    View in: PubMed
    Score: 0.008
  15. Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques. Proc Natl Acad Sci U S A. 2021 09 21; 118(38).
    View in: PubMed
    Score: 0.006
  16. Real-Time Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles. Cell Host Microbe. 2020 12 09; 28(6):880-891.e8.
    View in: PubMed
    Score: 0.005
  17. Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain. J Virol. 2005 Sep; 79(18):11638-46.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.